Design Therapeutics' reports lower-than-expected Q3 loss

Design Therapeutics

05/11/2025 21:17

Overview

Design Therapeutics reports lower-than-expected Q3 net loss of $17 mln

Company has $206 mln in cash, supporting pipeline advancement

Design nominates DT-818 for DM1, obtains ex-US regulatory clearance

Outlook

Company plans Phase 1 trial of DT-818 in Australia in H1 2026

Design expects data from DT-216P2 trial in H2 2026

Company anticipates DT-168 trial data in H2 2026

Result Drivers

R&D EXPENSES: Research and development (R&D) expenses were $14.59 mln compared to 11.9 mln a year earlier

G&A EXPENSES: General and administrative (G&A) expenses rose to $4.72 mln from $4.37 mln

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
Beat
-$17 mln
-$19.50 mln (3 Analysts)
Q3 Basic EPS
-$0.30
Q3 Operating Expenses
$19.31 mln
Q3 Operating Income
-$19.31 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Design Therapeutics Inc is $5.00, about 24.8% below its November 4 closing price of $6.24

Press Release: ID:nGNX8hW4tL

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)